Providing market intelligence for more than 35 years

In The News

The Apple Watch Has Gotten Simpler, But That’s OK

Apple’s decision to simplify the watch speaks to a larger issue facing makers of wearables: Advanced biotracking sensors would have made the Apple Watch less of a multipurpose consumer device and more of a medical device used to diagnose diseases or track chronic conditions — which could have opened the watch up to regulation by the U.S. Food and Drug Administration.

“I don’t think Apple wants to be a health-monitoring device maker,” said Harry Wang, director of health and mobile product research at Parks Associates. “They do want to leverage their popularity on the iPhone as a device platform, integrating all health data that can be collected for different devices.”

That information is being gathered through Apple’s new Health app, a dashboard of users’ health data, and HealthKit, a developer tool that lets wellness apps share data. The watch could be populated with messages from external devices and services that track specialized health information.

From the article "The Apple Watch Has Gotten Simpler, But That’s OK" by Stephanie M. Lee.

Previously In The News

Roku Stock Jumps After a Blowout Holiday Quarter

The Roku Channel is also turning heads. The company's ad-supported channel was named one of the three best ad-based over-the-top services among U.S. broadband households according to Parks Associates,...

Bulls vs. Bears: Who's Right About Roku Stock?

Roku faces myriad competitors, but it still dominated the U.S. streaming device market with a 37% share as of early 2018, according to Parks Associates. Amazon ranked second with a 28% share, and Appl...

AT&T Deal: Merger For New Media Era Or A Bad Remake?

Pay-TV operators are seeing a "slow erosion of the core business," analyst Brett Sappington at Parks Associates said. "After years of attempts to be more than just a 'dumb pipe,' pay-TV operators h...

The Simple Reason Why I Won't Buy Roku Inc.

Roku (NASDAQ:ROKU) went public on Sep. 28, its stock surging nearly 70% from its IPO price of $14 per share. The stock hit almost $30 the following day, but subsequently pulled back to the low $20s....